Articles tagged with Stomach Cancer
Researchers have discovered that JAK inhibitors, currently used to treat blood disorders, can reduce the growth of inflammation-associated stomach and bowel cancer. The study provides evidence supporting their use in treating these cancers.
Researchers have developed a tiny capsule that can detect occult blood in the stomach at very low levels, enabling early diagnosis of stomach cancer. The device is non-toxic and acid-safe, and has been shown to be reliable and simple to use.
A peptide fragment derived from cow's milk, lactoferricin B25, exhibits potent anticancer capability against human stomach cancer cell cultures. This finding provides support for the potential therapeutic agent for gastric cancer treatment.
Cancer is the leading cause of death among Hispanic Texans under 76, with lower rates of breast and colon cancer screenings. Despite advanced cancer stages at diagnosis, Hispanics experience higher survival rates than non-Hispanic whites.
Researchers discover how Helicobacter pylori suppresses human beta defensin 1 production, allowing bacteria to colonize and cause tissue damage. The study found that patients infected with H. pylori had ten times less hβD1 than uninfected patients.
Researchers identified three distinct molecular classifications of gastric cancer that respond differently to therapies, offering a promising new approach to treatment. The study found that tumors can be grouped into proliferative, metabolic and mesenchymal subtypes, each with unique genomic and epigenomic properties.
The UCLA School of Dentistry is developing a salivary biomarker panel to detect stomach cancer using exRNA biomarkers. The research has the potential to create a new paradigm in salivary diagnostics, revealing saliva's transformative potential for detecting systemic diseases.
Researchers at the Walter and Eliza Hall Institute have discovered that interleukin-11 is a key cytokine driving cancer development, unlike previously thought. Blocking its signalling could provide an exciting new approach to treating bowel and stomach cancers.
A study found genetic loci associated with H pylori seroprevalence through genome-wide association studies and meta-analysis. Genetic testing for H pylori susceptibility outside of research projects is premature due to the current approach's limitations.
Researchers at Virginia Tech discovered that Helicobacter pylori, a bacterium blamed for health issues like gastritis and gastric cancer, helps balance the stomach's ecosystem and control body weight and glucose tolerance in mice. The findings suggest that H. pylori may provide important metabolic traits required to combat diabetes.
The Case Western Reserve University School of Medicine has received a grant to study gastric cancers and explore the role of interleukin-33 (IL-33) in inflammation and its potential link to gastrointestinal cancers. The research aims to identify more effective treatments for these deadly diseases, which are currently incurable.
The 2013 Gastrointestinal Cancers Symposium revealed new advances in treating and prophesizing gastrointestinal cancers. The symposium presented five important studies, including a Phase III clinical trial showing that postoperative treatment with S-1 chemotherapy reduces relapses and extends survival in patients with pancreatic cancer.
Researchers have identified a complex of proteins that promotes the growth of some types of colon and gastric cancers, leading to the potential development of new treatments using mTorc1 inhibitors. The discovery is significant as it highlights the role of inflammation in cancer growth, particularly for colon and gastric cancers.
Researchers at SLAC National Accelerator Laboratory have identified a new way to attack Helicobacter pylori, a bacterium that causes ulcers and stomach cancer. By pinpointing the Achilles' heel of this tough bacteria, scientists hope to develop specific and effective treatments.
Researchers from UC Irvine and Cal State Fullerton are partnering to conduct pilot research projects on cancer health disparities in Orange County. The alliance will focus on erasing disparities in cervical, stomach, and liver cancers, as well as increasing awareness of the risks among different ethnic groups.
People with AIDS are at increased risk for developing esophageal and stomach carcinoma, as well as non-Hodgkin lymphomas. The study found that those with AIDS had a 69% increased risk of esophageal cancer and a 53% increased risk of lower stomach cancer.
A meta-analysis of 17 studies found that quitting alcohol significantly lowers the risk of esophageal cancer, with about half of this reduction occurring within 4-5 years. The study also suggests that moderate alcohol consumption may have beneficial health effects on cardiovascular disease and other conditions.
A large observational study found daily aspirin use associated with modestly lower cancer mortality, with significant reductions in gastrointestinal tract and certain other cancers. However, the study's findings are smaller than previous analyses, highlighting the need for further research to determine potential benefits.
A new study found that screening intervals between one and three years have similar outcomes for gastric cancer stages, but longer intervals lead to more advanced cancer at diagnosis. The researchers recommend a screening interval of every three years in high-risk regions.
The global cancer burden is projected to rise by over 75% by 2030, driven by demographic changes and Westernized lifestyle factors. Countries with low Human Development Index (HDI) are expected to experience a significant surge in cancer cases, particularly those associated with infection.
Researchers identified hundreds of novel genes mutated in stomach cancer, which could lead to targeted therapies. FAT4 and ARID1A were found to be particularly interesting, with mutations detected in 5% and 8% of stomach cancers, respectively.
Research by Sheila Collins and colleagues found that cardiac natriuretic peptides cause white fat cells to take on characteristics of brown fat cells, increasing energy usage. In another study, Anne Müller's team identified a cellular mechanism by which Helicobacter pylori protects against asthma by modulating immune cells.
A study published in Proceedings of the National Academy of Sciences reveals how Helicobacter pylori bacteria disrupts mitochondrial function to induce cell death. The researchers found that the bacterial toxin VacA recruits a host protein to activate apoptosis, a process linked to cancer development.
Research reveals that Helicobacter pylori causes DNA breaks in gastric mucosa cells, triggering genetic mutations and cell death. The study's findings suggest that prolonged infections can lead to exhaustion of the cell's repair response, exacerbating gastric carcinogenesis.
A recent study from MIT shows that estrogen dramatically lowers the rates of stomach cancer in male mice treated with the bacterium Helicobacter pylori. The researchers found that estrogen interferes with the recruitment and activity of immune cells, promoting inflammation and ultimately leading to gastritis and cancer.
A newly discovered hybrid gene is found to play a role in some stomach cancers, potentially fueling tumor growth and survival. The CD44-SLC1A2 fusion gene may be at work in up to 2 percent of stomach cancers and could lead to improved therapies.
A study published in The Lancet found that low-dose aspirin reduces mortality from various cancers, including oesophagus, lung, stomach, pancreas, and possibly brain cancer, by 20-30% regardless of dose or smoking status. Benefit is seen with increasing age and may require at least five years of use for significant impact.
Researchers have discovered that Helicobacter pylori's CagA protein disables the tumor suppressor protein RUNX3 in host cells, leading to gastric cancer. The interaction between CagA and RUNX3 causes degradation of the protein via ubiquitination, promoting aberrant cell growth and cancer development.
A recent study found that gastric cancer incidence has declined globally over the past 30 years for all age groups and races, except for young white adults. The majority of noncardia gastric cancers are attributed to chronic Helicobacter pylori infection.
A new study found that ghrelin improved appetite and food intake in gastric cancer patients who had part or all of their stomach removed. Body weight loss was significantly lower in the ghrelin group compared to the placebo group, indicating a potential benefit for these patients.
A large multicenter trial in Japan found that patients with early gastric cancer who received H. pylori antibiotics after surgical resection had a significantly lower risk of developing gastric cancer. Certain strains of H. pylori may carry an increased risk of developing gastric cancer, but more research is needed to fully understand ...
Researchers have found that Helicobacter pylori directly activates an enzyme in host cells associated with several types of cancer. Chronic H. pylori infection is a known risk factor for gastric cancer, and the discovery may lead to new treatments for this devastating disease.
A team of Duke and Singapore scientists have discovered a new way to classify gastric cancers based on the signaling pathways used to grow and spread. This new system may lead to more effective treatments and improved long-term survival for patients, as it allows for stratification according to tumor pathway profiles.
The report finds Hispanic/Latino Americans have a unique cancer risk profile, with lower incidence rates for all cancers combined, but higher rates of stomach, cervix, liver, and gallbladder cancers. They also experience later stage diagnoses for many cancers, including breast and melanoma.
A study in Korea found that individuals with low income, education level, and unhealthy behaviors tend to not use gastric cancer screening services. Targeted interventions and public campaigns can help improve screening participation for these vulnerable populations.
A recent study suggests that gastrin is an essential cofactor for Helicobacter-associated gastric corpus carcinogenesis in mice. High levels of gastrin lead to the development of stomach cancer, while absence of gastrin increases tumor numbers in the gastric antrum.
Researchers found that gastrin stimulates gastric acid secretion and plays a significant role in the development of Helicobacter-induced stomach cancer. High levels of gastrin may increase cancer risk, while low levels may lead to more tumors in specific parts of the stomach.
A new DNA stool test has been developed by Mayo Clinic researchers to detect digestive cancers in multiple organs, including pancreas, stomach, and esophageal cancers. The test was shown to be highly sensitive, detecting cancers at each organ site with high accuracy.
A new study predicts a significant increase in US cancer cases over the next 20 years, with the elderly and minority populations bearing the brunt. The projected 45% rise in cancer incidence will be driven primarily by a 67% increase in cancer cases among adults aged 65 and older.
A recent study published in World Journal of Gastroenterology reveals that only 10% of stomach cancer cases in Chile survived 5 years due to late consultation. This highlights the importance of implementing cost-effective mass early detection programs, particularly in high-risk areas.
A new study led by Memorial Sloan-Kettering Cancer Center compares traditional 'open' surgery to laparoscopic gastrectomy, a minimally invasive procedure. The findings demonstrate that laparoscopic surgeries yielded shorter hospital stays and fewer complications after surgery while maintaining similar rates of recurrence-free survival.
Researchers found that eating broccoli sprouts daily for eight weeks significantly reduced Helicobacter pylori infection levels in humans. This reduction is expected to lead to a decrease in stomach cancer risk due to the well-established cause-and-effect link between H. pylori and stomach cancer.
Eating two and a half ounces of baby broccoli sprouts daily for two months reduced HpSA levels by over 40% in infected individuals, suggesting potential protection against gastritis, ulcers, and stomach cancer. However, the study did not cure infection or eradicate H. pylori colonization.
A recent study by ECCO-the European CanCer Organisation analyzed data from the EUROCARE-4 Working Group, revealing a steady rise in cancer survival rates across Europe. The proportion of patients cured of lung, stomach, and colorectal cancers increased significantly between 1988-1990 and 1997-1999.
Researchers developed a non-invasive diagnostic tool using serum biomarker tests to differentiate between healthy and diseased stomach mucosa. The European GastroPanel examination, combined with pepsinogen assays, showed high accuracy in detecting gastric atrophy and peptic ulcer diseases.
Researchers found that PPAR-gamma ligands can suppress stomach cancer cell proliferation by inducing apoptosis and arresting the G1 phase. The study also showed that these compounds may be useful for targeting therapy of gastric cancer.
Researchers demonstrate feasibility and safety of magnetic-anchor-guided endoscopic submucosal dissection (MAG-ESD) for large early gastric cancer in humans. The technique facilitates en bloc removal of lesions by providing retraction capability using magnets, simplifying the procedure.
A nationwide study has confirmed the effectiveness of positron emission tomography (PET) in monitoring tumor activity and changing treatment plans for more than one out of three cancer patients. PET was found to be clinically significant, resulting in a change in treatment in 36% of cases.
A recent study discovered that Helicobacter pylori bacteria can be found in the mouths of people with halitosis without showing signs of stomach disease. The researchers found a significant association between the presence of H. pylori and periodontal disease, which is also a cause of bad breath.
Researchers at Columbia University Medical Center have discovered that elevated levels of interleukin-1 beta can initiate the progression towards stomach cancer. The study found that IL-1β works by activating myeloid derived suppressor cells, which are pro-inflammatory and contribute to gastric inflammation.
A new study reveals that H. pylori bacteria can exploit stomach cells to protect themselves from the immune system, increasing the risk of stomach cancer. The bacteria's interaction with gastric cells triggers a receptor called Decay-accelerating factor (DAF), which reduces immune damage and promotes chronic inflammation.
A randomized controlled trial found that removing H. pylori bacteria from stomachs of post-operative stomach cancer patients can significantly reduce the risk of stomach cancer redeveloping. The study showed a two-thirds reduction in metachronous gastric cancer development between eradication and control groups.
Researchers at Rhode Island Hospital have identified two proteins, GKN1 and GKN2, which are produced by normal stomach cells. Patients with poor outcomes following surgery for stomach cancer had extremely low amounts of these proteins. The discovery may help physicians better determine and individualize therapy for stomach cancer.
Researchers at MIT have confirmed the long-suspected link between chronic inflammation and increased cancer risk. Chronic stomach inflammation damages DNA, which can lead to mutations that cause cancer. Individuals with poor DNA repair systems may be more susceptible to developing cancer associated with chronic inflammation.
A study by OHSU Cancer Institute researchers found that nearly 67% of stomach cancer patients are not getting the best therapy, despite compelling clinical data available since 2001. The study also showed a five-month survival advantage for patients who received chemotherapy and radiation therapy.
Researchers found that prompt antibiotic treatment of H. pylori infections can reverse damage to the stomach lining and prevent gastric cancer. Treating mice with antibiotics at an early point of infection delayed the development of severe lesions that can lead to cancer.
The IL-11 protein is identified as the primary driver of tumor development in the stomach, promoting chronic inflammation and tumorigenesis by inducing excessive activation of Stat3. Inhibiting this signaling pathway prevents or reduces tumorigenesis in a mouse model of gastric cancer, offering hope for the development of new treatments.
Researchers at Stanford University School of Medicine developed a new medical imaging technology that can detect early stages of colon cancer without a biopsy. The technique uses a short protein attached to fluorescent beacon to identify cancerous cells, allowing doctors to pick up the earliest possible cancers.
Researchers have discovered gastric progenitor cells in mouse stomachs, which can give rise to all functional stomach glands. This discovery may aid understanding of normal cell turnover and potentially open doors for investigating gastric cancer origins.
Research published in the journal Gut indicates a projected 25% decline in stomach cancer cases in Western countries by 2030. The long-term nationwide study monitored three types of cell changes indicative of stomach cancer, tracking almost 98,000 patients from 1991 to 2005.